These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 20191333)

  • 1. Safe switching from dasatinib to nilotinib after a 1-month off-drug period for persistent pleural effusion in patients with chronic myelogenous leukemia in chronic phase.
    Nagata Y; Fukuda S; Kobayashi T; Yamashita T; Ohashi K; Sakamaki H; Akiyama H
    Int J Hematol; 2010 Apr; 91(3):539-41. PubMed ID: 20191333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NICE guidance on dasatinib, high-dose imatinib, and nilotinib for patients with CML who are resistant or intolerant to imatinib.
    Goulden S; Sutcliffe F; Stevens A
    Lancet Oncol; 2012 Feb; 13(2):127-8. PubMed ID: 22403810
    [No Abstract]   [Full Text] [Related]  

  • 3. Pleural/pericardic effusions during dasatinib treatment: incidence, management and risk factors associated to their development.
    Breccia M; Alimena G
    Expert Opin Drug Saf; 2010 Sep; 9(5):713-21. PubMed ID: 20722490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib for the treatment of Philadelphia chromosome-positive chronic myelogenous leukaemia after imatinib failure.
    Hochhaus A
    Expert Opin Pharmacother; 2007 Dec; 8(18):3257-64. PubMed ID: 18035968
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Management of chronic myeloid leukemia].
    Kubuki Y
    Rinsho Ketsueki; 2008 Oct; 49(10):1401-10. PubMed ID: 18833925
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase.
    Cortes J; Kim DW; Raffoux E; Martinelli G; Ritchie E; Roy L; Coutre S; Corm S; Hamerschlak N; Tang JL; Hochhaus A; Khoury HJ; Brümmendorf TH; Michallet M; Rege-Cambrin G; Gambacorti-Passerini C; Radich JP; Ernst T; Zhu C; Van Tornout JM; Talpaz M
    Leukemia; 2008 Dec; 22(12):2176-83. PubMed ID: 18754032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cross-intolerance to imatinib, dasatinib and nilotinib therapy in a patient with chronic myeloid leukaemia.
    Novitzky-Basso I; Craddock C
    Eur J Haematol; 2011 Jun; 86(6):548-9. PubMed ID: 21477076
    [No Abstract]   [Full Text] [Related]  

  • 9. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study.
    Hiwase D; Tan P; D'Rozario J; Taper J; Powell A; Irving I; Wright M; Branford S; Yeung DT; Anderson L; Gervasio O; Levetan C; Roberts W; Solterbeck A; Traficante R; Hughes T
    Leuk Res; 2018 Apr; 67():109-115. PubMed ID: 29494928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Beyond dose escalation: clinical options for relapse or resistance in chronic myelogenous leukemia.
    Cortes J; Kantarjian H
    J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S22-S30. PubMed ID: 18397678
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.
    Cortes J; Rousselot P; Kim DW; Ritchie E; Hamerschlak N; Coutre S; Hochhaus A; Guilhot F; Saglio G; Apperley J; Ottmann O; Shah N; Erben P; Branford S; Agarwal P; Gollerkeri A; Baccarani M
    Blood; 2007 Apr; 109(8):3207-13. PubMed ID: 17185463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis.
    Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R
    Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dasatinib, large granular lymphocytosis, and pleural effusion: useful or adverse effect?
    Paydas S
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):242-7. PubMed ID: 24210599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure.
    Quintás-Cardama A; Kantarjian H; O'brien S; Borthakur G; Bruzzi J; Munden R; Cortes J
    J Clin Oncol; 2007 Sep; 25(25):3908-14. PubMed ID: 17761974
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failure.
    Quintas-Cardama A; Kantarjian H; Jones D; Nicaise C; O'Brien S; Giles F; Talpaz M; Cortes J
    Blood; 2007 Jan; 109(2):497-9. PubMed ID: 16990591
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia.
    Latagliata R; Breccia M; Fava C; Stagno F; Tiribelli M; Luciano L; Gozzini A; Gugliotta G; Annunziata M; Cavazzini F; Ferrero D; Musto P; Capodanno I; Iurlo A; Visani G; Crugnola M; Calistri E; Castagnetti F; Vigneri P; Alimena G
    Hematol Oncol; 2013 Jun; 31(2):103-9. PubMed ID: 22815278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pleural and pericardial effusions in chronic myeloid leukemia patients receiving low-dose dasatinib therapy.
    Eskazan AE; Soysal T; Ongoren S; Gulturk E; Ferhanoglu B; Aydin Y
    Haematologica; 2011 Mar; 96(3):e15; author reply e16-7. PubMed ID: 21357709
    [No Abstract]   [Full Text] [Related]  

  • 19. Nilotinib can override dasatinib resistance in chronic myeloid leukemia patients with secondary resistance to imatinib first-line therapy.
    Breccia M; Cannella L; Nanni M; Stefanizzi C; Alimena G
    Acta Haematol; 2007; 118(3):162-4. PubMed ID: 17890849
    [No Abstract]   [Full Text] [Related]  

  • 20. Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
    Kelly K; Swords R; Mahalingam D; Padmanabhan S; Giles FJ
    Target Oncol; 2009 Apr; 4(2):99-105. PubMed ID: 19381453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.